{"id":"NCT00094770","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)","officialTitle":"A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK0431 Compared With Sulfonylurea Therapy in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2006-05","completion":"2007-05","firstPosted":"2004-10-25","resultsPosted":"2009-12-22","lastUpdate":"2016-08-26"},"enrollment":1172,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"sitagliptin (MK0431)","otherNames":["MK0431"]},{"type":"DRUG","name":"Comparator: glipizide","otherNames":["Glipizide"]}],"arms":[{"label":"Sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Glipizide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this investigational study is to determine the safety and effectiveness of an investigational drug in patients with type 2 diabetes mellitus (a specific type of diabetes).","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 52","timeFrame":"Baseline and Week 52","effectByArm":[{"arm":"Sitagliptin 100 mg","deltaMin":-0.67,"sd":null},{"arm":"Glipizide","deltaMin":-0.67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17300595","25633134","21477878","20456211"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":588},"commonTop":["Hypoglycaemia","Upper Respiratory Tract Infection","Nasopharyngitis","Diarrhoea","Bronchitis"]}}